RxDoctor Payments Data

Anna Stern, MD

General Practice · la Jolla, CANPI 1184728834

Payments from drug & device makers

$5,061in general payments, 2019–2025

Across 255 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$860
  • AbbVie$447
  • GSK$363
  • Teva Pharmaceuticals USA, Inc.$316
  • Novartis$285
  • AstraZeneca$265
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,047100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,061 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$10,044
Medicare patients
38
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$39,234
EliquisApixaban26$26,878
JardianceEmpagliflozin20$24,230
Atorvastatin Calcium116$1,477
SynthroidLevothyroxine Sodium16$1,324
Levothyroxine Sodium57$1,018
Rosuvastatin Calcium66$915
Tramadol Hcl12$718
Albuterol Sulfate HfaAlbuterol Sulfate41$691
Losartan Potassium62$591
Ezetimibe28$554
Venlafaxine Hcl ErVenlafaxine Hcl11$530
Alendronate Sodium43$415
Lisinopril47$414
FenofibrateFenofibrate Nanocrystallized15$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$233$39,23437 claims
PfizerEliquis$126$26,87826 claims
Boehringer IngelheimJardiance$19$24,23020 claims
AbbVieSynthroid$447$1,32416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →